From the bench to the bedside: ways to improve rituximab efficacy.

Blood
Guillaume CartronPhilippe Solal-Celigny

Abstract

Rituximab (MabThera, Rituxan) is a chimeric IgG1 monoclonal antibody that specifically targets the CD20 surface antigen expressed on normal and neoplastic B-lymphoid cells. Rituximab is currently used in the treatment of both follicular and aggressive B-cell non-Hodgkin lymphomas. Despite its demonstrated clinical effectiveness, its in vivo mechanisms of action remain unknown and could differ by subtype of lymphoma. Rituximab has been shown to induce apoptosis, complement-mediated lysis, and antibody-dependent cellular cytotoxicity in vitro, and some evidence points toward an involvement of these mechanisms in vivo. Rituximab also has a delayed therapeutic effect as well as a potential "vaccinal" effect. Here, we review the current understanding of the mechanism of action of rituximab and discuss approaches that could increase its clinical activity. A better understanding of how rituximab acts in vivo should make it possible to develop new and more effective therapeutic strategies.

References

Dec 1, 1992·European Journal of Immunology·M A Valentine, K A Licciardi
Mar 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·E A ClarkJ A Ledbetter
Oct 22, 1993·Cell·D M HockenberyS J Korsmeyer
Mar 1, 1993·European Journal of Immunology·I BourgetJ L Cousin
Mar 1, 1996·Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy·S FunakoshiW J Murphy
Jan 1, 1997·Trends in Biotechnology·A Wright, S L Morrison
Oct 23, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D G MaloneyR Levy
Feb 12, 1998·Transplantation·S BuysmannI J ten Berge
Feb 7, 1998·The Journal of Biological Chemistry·J P DeansJ A Savage
Jun 20, 1998·Immunogenetics·T L O'KeefeM S Neuberger
Aug 15, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P McLaughlinB K Dallaire
Nov 18, 1998·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N L BerinsteinD Shen
Feb 5, 1999·European Journal of Immunology·R DyallJ Nikolić-Zugić
Feb 5, 1999·European Journal of Immunology·C LéveilléW Mourad
Mar 31, 2000·Nature Medicine·R A ClynesJ V Ravetch
Feb 7, 2001·Cancer Immunology, Immunotherapy : CII·D ShanO W Press
Feb 7, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·E E IdusogieM G Mulkerrin
Aug 30, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T A DavisR Levy
Feb 13, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·E E IdusogieM G Mulkerrin
Feb 15, 2002·British Journal of Haematology·L E van der KolkM H van Oers

❮ Previous
Next ❯

Citations

Nov 2, 2004·Der Internist·C BuskeW Hiddemann
Apr 7, 2007·Cancer Immunology, Immunotherapy : CII·Greta GarridoLuis E Fernández
Sep 4, 2009·Annals of Hematology·Andrea BorgerdingLorenz Trümper
Jan 29, 2011·Cancer Metastasis Reviews·Roch HouotRonald Levy
Jan 27, 2011·Cancer Metastasis Reviews·Riad Abès, Jean-Luc Teillaud
Sep 6, 2008·Molecular Imaging and Biology : MIB : the Official Publication of the Academy of Molecular Imaging·S A JacobsK S McCarty
Oct 1, 2007·Current Hematologic Malignancy Reports·Jane N Winter
Jan 9, 2010·International Journal of Hematology·Joseph E Kiss
Jul 26, 2012·Blood Cancer Journal·B E WahlinE Kimby
Jan 21, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Antonio FontanellasIgnacio Melero
Jul 4, 2006·Nature Reviews. Drug Discovery·Jeffrey L Browning
Feb 9, 2008·Nature Reviews. Drug Discovery·Kresten SkakPallavur V Sivakumar
Feb 2, 2011·Nature Reviews. Drug Discovery·Xu-Rong JiangMark Schenerman
Apr 20, 2006·Nature Reviews. Immunology·Paul J Carter
Apr 24, 2010·Nature Reviews. Immunology·Louis M WeinerShangzi Wang
Jan 23, 2013·Nature Reviews. Nephrology·Aditi Sinha, Arvind Bagga
May 29, 2007·Oncogene·B Coiffier
Dec 29, 2009·Médecine sciences : M/S·Guillaume Cartron, Jean-François Rossi
Aug 9, 2008·The New England Journal of Medicine·Bruce D Cheson, John P Leonard
Jul 11, 2012·The Journal of Biological Chemistry·Irina V BalyasnikovaMaciej S Lesniak
Apr 15, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G CartronH Watier
Apr 29, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K A BlumUNKNOWN Cancer and Leukemia Group B
Dec 8, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E J O SoiniT Nousiainen
Jul 12, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P ColombatP Solal-Celigny
Jan 25, 2008·Transplantation·Helena GenbergGunnar Tydén
Nov 15, 2011·Current Opinion in Hematology·Ofir WolachMeir Lahav
Oct 22, 2005·Annals of the Rheumatic Diseases·E A Clark, J A Ledbetter
Nov 5, 2005·Annals of the Rheumatic Diseases·K P NgD A Isenberg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis